Cellectis SA (CLLS)
NASDAQ:CLLS
Want to see CLLS full AI Analyst Report?
Top Page
Cellectis SA
(NASDAQ:CLLS)
Select Model
Select Model
Rating:50Neutral
Price Target:
$3.50
▼(-20.81% Downside)
Action:ReiteratedDate:04/14/26
The score is held back primarily by weak financial performance—persistent losses, renewed 2025 cash burn, and rising leverage—partly offset by a relatively constructive technical setup with the stock trading above several key moving averages. Valuation is constrained by negative earnings and the absence of a dividend.
Positive Factors
In-house manufacturing & value-chain control
Owning end-to-end manufacturing and operating hubs in France and the U.S. is a durable strategic advantage for allogeneic cell therapies: it improves supply reliability, accelerates clinical-to-regulatory timelines, supports quality control and partner confidence, and reduces long-term dependency on contract manufacturers.
Negative Factors
Persistent losses and renewed cash burn
Ongoing operating and net losses that resumed material cash burn in 2025 are a structural concern: they necessitate recurrent external funding, erode internal resources for R&D, and increase dependency on milestone or licensing inflows to reach self-sustaining operations absent commercial revenues.
Read all positive and negative factors
Positive Factors
Negative Factors
In-house manufacturing & value-chain control
Owning end-to-end manufacturing and operating hubs in France and the U.S. is a durable strategic advantage for allogeneic cell therapies: it improves supply reliability, accelerates clinical-to-regulatory timelines, supports quality control and partner confidence, and reduces long-term dependency on contract manufacturers.
Read all positive factors
Cellectis SA (CLLS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$267.09M
Dividend YieldN/A
Average Volume (3M)51.10K
Price to Earnings (P/E)―
Beta (1Y)1.01
Revenue Growth76.18%
EPS Growth-109.46%
CountryUS
Employees216
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.68
Shares Outstanding72,325,455
10 Day Avg. Volume53,256
30 Day Avg. Volume51,104
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)6.39
Price to Sales (P/S)6.63
P/FCF Ratio-11.42
Enterprise Value/Market Cap1.22
Enterprise Value/Revenue4.46
Enterprise Value/Gross Profit5.15
Enterprise Value/Ebitda-8.17
Forecast
1Y Price Target
$9.00Price Target Upside103.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.09
Revenue Forecast (FY)$61.17M
Cellectis SA Business Overview & Revenue Model
Company Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics ...
How the Company Makes Money
Cellectis generates revenue primarily through (1) collaboration and partnership arrangements and (2) other operating income, with product sales generally not being a significant source while its therapeutic candidates remain in development.
1) Co...
Cellectis SA Earnings Call Summary
Earnings Call Date:Aug 04, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:May 11, 2026
Earnings Call Sentiment Positive
The earnings call reflects a generally positive sentiment, driven by progress in clinical trials and strategic partnerships, despite financial and legal challenges. The successful advancement of pivotal trials and the strong collaboration with AstraZeneca are significant positives. However, the arbitration with Servier presents a notable uncertainty.Positive Updates
Pivotal Phase II Trial Initiation
Cellectis is preparing to initiate a pivotal Phase II trial for lasme-cel, UCART22, in relapsed or refractory acute lymphoblastic leukemia in the second half of 2025, following successful end of Phase I discussions with the FDA and EMA.
Negative Updates
Servier Arbitration Uncertainty
Cellectis is involved in ongoing arbitration with Servier and Allogene, seeking to terminate the agreement and receive compensation for losses and milestone payments due to halted CD19 product development.
Read all updates
Q2-2025 Updates
Positive
Negative
Pivotal Phase II Trial Initiation
Cellectis is preparing to initiate a pivotal Phase II trial for lasme-cel, UCART22, in relapsed or refractory acute lymphoblastic leukemia in the second half of 2025, following successful end of Phase I discussions with the FDA and EMA.
Read all positive updates
Company Guidance
During the Cellectis Second Quarter 2025 Earnings Call, the company provided extensive guidance on several key metrics and strategic initiatives. Cellectis announced plans to host an Investor R&D Day on October 16, 2025, in New York City, where they will present Phase I data and a late-stage development strategy for lasme-cel, UCART22, in relapsed or refractory acute lymphoblastic leukemia. The pivotal Phase II trial for lasme-cel is set to begin in the second half of 2025, following productive discussions with the FDA and EMA. The company also updated on their arbitration proceedings with Servier, with a decision expected by December 15, 2025. Financially, Cellectis reported a cash position of $230 million as of June 30, 2025, sufficient to fund operations into the second half of 2027. This includes the costs associated with the pivotal studies for lasme-cel and eti-cel. Additionally, the company shared progress on their collaboration with AstraZeneca, which includes three cell and gene therapy programs.Cellectis SA Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
41
Neutral
Cash Flow
27
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 73.17M | 41.51M | 755.00K | 19.17M | 30.35M |
| Gross Profit | 53.05M | 32.32M | -6.66M | 10.69M | 28.50M |
| EBITDA | -20.36M | -9.46M | -92.64M | -76.38M | -78.42M |
| Net Income | -67.80M | -36.76M | -101.06M | -106.14M | -114.20M |
Balance Sheet | |||||
| Total Assets | 324.72M | 383.54M | 334.27M | 261.22M | 382.08M |
| Cash, Cash Equivalents and Short-Term Investments | 208.66M | 260.31M | 203.81M | 97.70M | 186.13M |
| Total Debt | 119.90M | 91.46M | 85.06M | 75.77M | 100.87M |
| Total Liabilities | 248.82M | 252.51M | 249.57M | 135.28M | 145.60M |
| Stockholders Equity | 75.90M | 131.03M | 84.69M | 117.97M | 221.29M |
Cash Flow | |||||
| Free Cash Flow | -42.50M | 19.52M | -25.82M | -89.89M | -123.12M |
| Operating Cash Flow | -40.14M | 22.10M | -24.75M | -87.44M | -104.56M |
| Investing Cash Flow | -29.58M | -102.63M | -15.51M | -2.76M | 7.28M |
| Financing Cash Flow | -16.20M | 89.80M | 82.86M | 1.15M | 47.52M |
Cellectis SA Technical Analysis
Positive
4.42
Price Trends
3.66
Positive
4.08
Positive
3.55
Positive
Market Momentum
0.17
Negative
68.79
Neutral
76.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLLS, the sentiment is Positive. The current price of 4.42 is above the 20-day moving average (MA) of 3.57, above the 50-day MA of 3.66, and above the 200-day MA of 3.55, indicating a bullish trend. The MACD of 0.17 indicates Negative momentum. The RSI at 68.79 is Neutral, neither overbought nor oversold. The STOCH value of 76.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLLS.
Cellectis SA Risk Analysis
Cellectis SA disclosed 102 risk factors in its most recent earnings report. Cellectis SA reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cellectis SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $504.77M | -2.69 | -83.86% | ― | ― | -103.45% | |
50 Neutral | $267.09M | -4.62 | -69.63% | ― | 76.18% | -109.46% | |
50 Neutral | $274.72M | -3.92 | 88.31% | ― | 36.75% | 27.97% | |
47 Neutral | $718.55M | 0.02 | 72.70% | ― | ― | -880.05% | |
44 Neutral | $203.61M | -1.05 | 279.62% | ― | ― | ― | |
44 Neutral | $171.43M | -1.35 | -85.20% | ― | ― | 52.32% |
* Healthcare Sector Average
CLLS
Cellectis SA
3.70
2.12
134.18%
RNAC
Cartesian Therapeutics
6.93
-3.64
-34.44%
FHTX
Foghorn Therapeutics
4.68
0.70
17.59%
VOR
Vor Biopharma
14.71
3.41
30.18%
TNYA
Tenaya Therapeutics
0.79
0.32
69.53%
ZURA
Zura Bio
5.32
4.10
336.07%
Cellectis SA Corporate Events
Cellectis to Release First-Quarter 2026 Results on May 11
May 4, 2026
Cellectis S.A., a clinical-stage biotechnology company specializing in off-the-shelf gene-edited CAR T-cell therapies and broader cell and gene therapy platforms, maintains full control of its value chain through in-house manufacturing and operate...
Cellectis Showcases Safer Epigenetic Gene-Silencing Platform Ahead of ASGCT 2026
Apr 27, 2026
On April 27, 2026, Cellectis announced that it is presenting new data on a TALE-based epigenetic editing platform at the American Society of Gene and Cell Therapy annual meeting in Boston, scheduled for May 11–15, 2026. The approach uses TAL...
Cellectis Highlights Positive Pivotal Interim Data for Allogeneic CAR-T Partnered Cema-cel
Apr 13, 2026
On April 13, 2026, Cellectis reported that interim futility data from Allogene Therapeutics’ pivotal ALPHA3 trial in first-line consolidation for large B-cell lymphoma showed strong minimal residual disease clearance for cema-cel, an allogen...
Cellectis Posts 2025 Results, Highlights Strong Allogeneic CAR-T Data and Cash Runway Into 2027
Mar 20, 2026
On March 19, 2026, Cellectis reported full-year 2025 financial results and a business update, highlighting progress on its allogeneic CAR-T portfolio and gene-editing technologies. As of December 31, 2025, the company held $211 million in cash, ca...
Cellectis S.A. Sets March 19 Release Date for Q4 and Full-Year 2025 Results
Mar 12, 2026
Cellectis S.A., a clinical-stage biotechnology company specializing in gene-edited, off-the-shelf CAR T-cell therapies and other cell and gene therapies, operates an end-to-end platform with in-house manufacturing across sites in Paris, New York a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.